MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com
Clinical Trials
Related News

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Completed
Conditions
Multiple Sclerosis
Interventions
First Posted Date
2009-12-14
Last Posted Date
2012-01-05
Lead Sponsor
Bayer
Target Recruit Count
176
Registration Number
NCT01031459

Xarelto Regulatory Post-Marketing Surveillance

Completed
Conditions
Venous Thromboembolism
Interventions
Drug: Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
First Posted Date
2009-12-10
Last Posted Date
2017-01-23
Lead Sponsor
Bayer
Target Recruit Count
3388
Registration Number
NCT01029743

To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Neoplasms
Interventions
First Posted Date
2009-12-09
Last Posted Date
2015-01-21
Lead Sponsor
Bayer
Target Recruit Count
12
Registration Number
NCT01028755

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

Phase 3
Completed
Conditions
Blood Coagulation Disorders
Hemophilia A
Interventions
Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Biological: Recombinant Factor VIII (BAY81-8973)
First Posted Date
2009-12-09
Last Posted Date
2016-11-28
Lead Sponsor
Bayer
Target Recruit Count
74
Registration Number
NCT01029340
Locations
🇸🇪

Karolinska Universitetssjukhuset i Solna, Stockholm, Sweden

Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain

Phase 3
Completed
Conditions
Low Back Pain
Interventions
Drug: Placebo
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
First Posted Date
2009-12-09
Last Posted Date
2009-12-09
Lead Sponsor
Bayer
Target Recruit Count
338
Registration Number
NCT01028079

Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia

Phase 2
Completed
Conditions
Pneumonia
Interventions
First Posted Date
2009-11-30
Last Posted Date
2016-02-18
Lead Sponsor
Bayer
Target Recruit Count
30
Registration Number
NCT01021436

Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo

Phase 2
Completed
Conditions
Tinea Pedis
Interventions
Drug: Placebo
First Posted Date
2009-11-16
Last Posted Date
2015-01-27
Lead Sponsor
Bayer
Target Recruit Count
220
Registration Number
NCT01013909

Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation

Phase 1
Completed
Conditions
QTc Evaluation
Electrocardiography
Interventions
Drug: Placebo
First Posted Date
2009-11-16
Last Posted Date
2013-06-03
Lead Sponsor
Bayer
Target Recruit Count
56
Registration Number
NCT01014247

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Phase 3
Completed
Conditions
Retinal Vein Occlusion
Interventions
Other: Sham treatment
Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
First Posted Date
2009-11-13
Last Posted Date
2014-11-02
Lead Sponsor
Bayer
Target Recruit Count
177
Registration Number
NCT01012973

Regulatory Post Marketing Surveillance Study on Nexavar®

Completed
Conditions
Carcinoma, Renal Cell
Carcinoma, Hepatocellular
Interventions
First Posted Date
2009-11-11
Last Posted Date
2015-09-21
Lead Sponsor
Bayer
Target Recruit Count
2845
Registration Number
NCT01012011
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy